Bortezomib co-treated GBM patients with methylated MGMT promoter survived for much longer than patients treated with adjuvant TMZ only, with a median PFS of 24.7 months for the bortezomib group and 10.3/14.1 months for historical control groups from two previously published studies, and a median OS of 49.4 months and 21.7/23.2 months, respectively [50]. This evidence concerns the gene MGMT and glioblastoma.